2020
Differential effects of PD-L1 versus PD-1 blockade on myeloid inflammation in human cancer
Bar N, Costa F, Das R, Duffy A, Samur M, McCachren S, Gettinger S, Neparidze N, Parker TL, Bailur JK, Pendleton K, Bajpai R, Zhang L, Xu ML, Anderson T, Giuliani N, Nooka A, Cho HJ, Raval A, Shanmugam M, Dhodapkar KM, Dhodapkar M. Differential effects of PD-L1 versus PD-1 blockade on myeloid inflammation in human cancer. JCI Insight 2020, 5 PMID: 32427579, PMCID: PMC7406262, DOI: 10.1172/jci.insight.129353.Peer-Reviewed Original ResearchConceptsPD-L1 blockadePD-1 blockadeAsymptomatic multiple myelomaMonocyte-derived DCsPD-L1Immunologic effectsT cellsMyeloid cellsAntigen-specific T cell expansionAnti-PD-1 therapyMyeloid antigen-presenting cellsDistinct inflammatory signatureSystemic immunologic effectsLung cancer patientsT cell expansionAntigen-presenting cellsMyeloid activationMyeloid inflammationInflammatory signatureNIH/NCICheckpoint blockadeDC maturationL1 therapyCombination therapyInflammatory phenotype
2018
Microenvironment Cell Contribution to Lymphoma Immunity
Kumar D, Xu ML. Microenvironment Cell Contribution to Lymphoma Immunity. Frontiers In Oncology 2018, 8: 288. PMID: 30101129, PMCID: PMC6073855, DOI: 10.3389/fonc.2018.00288.Peer-Reviewed Original ResearchLymphoma-associated macrophagesMesenchymal stem/stromal cellsT cellsLymphoma microenvironmentStromal cellsMarkers of exhaustionImmune checkpoint blockadeRegulatory T cellsEra of immunotherapyNatural killer cellsAnti-tumor effectsStem/stromal cellsLymphoma immunityTim-3Adverse eventsCheckpoint blockadeDendritic cellsImmune dysfunctionKiller cellsPD-1Immune cellsMechanisms of resistanceImmune escapeTumor surveillanceLAG-3